Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility
Blood tests show promise for catching pancreatic cancer earlier, though current evidence best supports their use alongside standard detection rather than as population screening alone.
Pancreatic ductal adenocarcinoma has dismal prognosis due to late diagnosis; blood-based liquid biopsy biomarkers including ctDNA, circulating tumor cells, extracellular vesicles, and circulating RNAs offer potential earlier-detection opportunities depending on clinical context. This review critically maps each biomarker class across six intended-use scenarios and concludes that current evidence supports ctDNA in molecular profiling but not yet in population screening for PDAC.
What the study was
- Study design
- Narrative review
- Category
- T3: Early cancer detection
- Maturity
- Exploratory
- Journal
- Frontiers in Oncology
Why it surfaced
PDAC has the worst 5-year survival of major cancers; this review delivers a clinically actionable intended-use framework for liquid biopsy deployment directly advancing the watchlist goal of early cancer detection in the highest-unmet-need tumor type.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.